Compare Stocks: DMT, DDDD, REDX, TILS, and SCLP

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMT Small Pharma	C$0.15 -6.3%	C$0.15	C$0.06 ▼ C$0.22	C$50.37M	0.86	296,159 shs	1.89 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMT Small Pharma	0.00%	0.00%	0.00%	0.00%	+100.00%

A new way to collect income from stocks (Ad)

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DMT Small Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMT Small Pharma	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMT Small Pharma	C$-1.16K	-43,343.80	C$0.13 per share	1.13	C$0.03 per share	5.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMT Small Pharma	-C$19.31M	-C$0.07	N/A	∞	N/A	N/A	-116.90%	-66.00%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMT Small Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMT Small Pharma	5.95	2.63	6.28

Ownership

Institutional Ownership

Company	Institutional Ownership
DMT Small Pharma	0.67%

Insider Ownership

Company	Insider Ownership
DMT Small Pharma	31.08%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
DMT Small Pharma	13	335.77 million	N/A	Not Optionable

DMT, DDDD, REDX, TILS, and SCLP Headlines

Source	Headline
	Navigating The Cookieless Era: How Pharma Adapts To Continual Disruption forbes.com - April 10 at 10:36 PM
	THE HIGH CHAMBER: Lawmaker wants to take shrooms on trip to governor’s desk inmaricopa.com - April 10 at 5:35 PM
	Poor Customer Data Management Costs Pharma Companies Money: Report biospace.com - April 10 at 7:34 AM
	The IRA Is Already Curtailing Small Molecule Drug Development. Here’s How to Reverse That. biospace.com - April 10 at 7:34 AM
	For biopharma M&A, the best returns come from small deals: analysts fiercepharma.com - April 9 at 11:32 AM
	FSD Pharma receives Nasdaq notification regarding minimum bid price deficiency msn.com - April 8 at 8:24 AM
	Are new treatments for multiple sclerosis on the horizon? labiotech.eu - March 28 at 11:15 AM
	Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton finance.yahoo.com - March 26 at 7:58 PM
	“Get on Your Knees”—Alberta Cops Raid Home Over Ayahuasca Delivery filtermag.org - March 20 at 11:37 PM
	The Next Great Biotech Boom Has Arrived informazione.it - March 19 at 12:40 PM
	Twenty-First Century Illicit Drugs and Their Discontents: Driving Down the Psychedelic Highway heritage.org - March 16 at 7:59 AM
	LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities msn.com - March 13 at 10:50 AM
	Could a psychedelic help solve Ohio’s opioid crisis? Ohio Treasurer just hired one of its biggest backers cleveland.com - March 11 at 5:13 PM
	Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7 businessinsider.com - March 9 at 8:02 AM
	Pharma major Roche launches breakthrough therapy to treat Multiple Sclerosis in India msn.com - February 27 at 12:13 PM
	Shannon is terminally ill. In a trailblazing trial, she took a white pill smh.com.au - February 23 at 7:44 PM
	Trxade sells online pharma marketplace, stock rallies 90% msn.com - February 20 at 3:44 PM
	Medford Massachusets Move To Decriminalize Psychedelics Has Statewide Reform Implications msn.com - February 15 at 12:58 PM
	Exxel Pharma Provides Business Overview and Upcoming Milestones star-telegram.com - January 25 at 8:19 PM
	What Happens in the Human Brain After Taking DMT? technologynetworks.com - January 22 at 1:14 PM
	The Distinct Cultures of Large and Small Pharmas, plus: Can Drug Developers Overcome The “Productivity Paradox” and Seize the AI Moment? aei.org - December 22 at 12:01 AM
	Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace statnews.com - December 21 at 9:00 AM
	Small Pharma Tackles Major Depression with Potentially Game Changing Psychedelic Therapy msn.com - December 5 at 9:44 AM
	Canadian Investment Regulatory Organization Trading Halt - DMT finance.yahoo.com - October 23 at 1:32 PM

Media Sentiment Over Time

Company Descriptions

Small Pharma

CVE:DMT

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

Compare Stocks